Resource persons Ms. Perla F. Baje, PAB-LAD Chief (right), and Ms. Japhet T. Celis, PAB-PDD Personnel (3rd from right) received the Certificate of Appreciation from Atty. Emilio L. Polig Jr. (center) Director II of FDA South Luzon Cluster

The Food and Drug Administration (FDA) South Luzon cluster had an orientation on ISO/IEC 17020:2012 during their Operational Planning and Team Building in Lumban Laguna on 28-31 May 2019.  Ms. Perla Baje, Chief, of Laboratory Accreditation Division of DTI-PAB was the main speaker while Ms. Japhet Celis provided information on DTI-PAB services.

ISO/IEC 17020 is an international standard that specifies requirements for the competence of bodies performing inspection and for the impartiality and consistency of their inspection activities. This standard applies to type A, B or C inspection bodies  as defined in ISO/IEC 17020:2012, and it applies to any stage of inspection. 

The Food and Drug Administration of the Philippines was created under the Department of Health to license, monitor, and regulate the flow of food, drugs, cosmetics, medical devices, and household hazardous waste in the Philippines.

Being updated with the international standards and requirements shows the FDA’s commitment to deliver high quality services to their clientele and to ensure the health and safety of food and drugs made available to the public.

DTI-PAB is the national accreditation body of the Philippines mandated to accredit inspection bodies, certification bodies, testing and certification laboratories and other bodies offering conformity assessment services. It also promotes accreditation through facilitations of briefings and orientation on the accreditation schemes currently being offered. As of 30 April 2019, DTI-PAB has accredited a total of 243 conformity assessment bodies (CABS) that include 166 testing laboratories, 46 calibration laboratories, 7 medical laboratories, 8 inspection bodies and 16 certification bodies.

For more information on accreditation and PAB services, please contact 0917-814-2344 or 0917-802-0047 or e-mail at 

Release Date: 04 June 2019